The manufacturer of strontium ranelate (Protelos®) communicated the intention to cease supply of this medicines in May 2017. In that notification it was advised that production and distribution would cease at the end of August 2017.
Licensed for the treatment of severe osteoporosis it has been the subject of several safety alerts over the years including life-threatening allergic reactions, venous thromboembolism and increased risk of heart problems. The manufacturer has taken a strategic decision, for commercial reasons, to withdraw the product.
Action: Clinicians should be aware of this product being discontinued. It would be prudent to run clinical system searches to identify any patients who are currently prescribed this product to allow a review and arrangements made to identify a suitable alternative.
|« CKS Updates - May 2017||SMC Update - June 2017 »|